

**COMPLETE LISTING OF ALL CLAIMS, WITH MARKINGS AND STATUS IDENTIFIERS**

(Currently amended claims showing deletions ~~by strikethrough~~ or [[double brackets]] and additions by underlining)

1 - 10 (canceled)

11 (previously presented): A human PTH analogue of the formula, [Cha<sup>7,11</sup>, des-Met<sup>8</sup>, Nle<sup>18</sup>, Tyr<sup>34</sup>]hPTH(1-34)NH<sub>2</sub> (SEQ ID NO:16), which selectively binds to the PTH2 receptor, or a pharmaceutically acceptable salt thereof.

12 - 51 (canceled)

52 (previously presented): A human PTH analogue which selectively binds to the PTH2 receptor, wherein said analogue is selected from the group consisting of

[Cha<sup>7,11</sup>, des-Met<sup>8</sup>, Nle<sup>18</sup>, Tyr<sup>34</sup>]hPTH(1-34)NH<sub>2</sub> (SEQ ID NO:16),

[Cha<sup>7,11</sup>, D-Nle<sup>8</sup>, des-Met<sup>18</sup>, Tyr<sup>34</sup>]hPTH(1-34)NH<sub>2</sub>, and

[Cha<sup>7,11</sup>, D-Nle<sup>8</sup>, Nle<sup>18</sup>, Tyr<sup>34</sup>]hPTH(1-34)NH<sub>2</sub>,

which selectively binds to the PTH2 receptor, or a pharmaceutically acceptable salt thereof.

53 (previously presented): A pharmaceutical composition comprising an analogue according to claim 52 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

54 (canceled)

55 (canceled)